Marker Therapeutics, Inc.

Marker Therapeutics, Inc.

Pharmaceutical Manufacturing

Houston, Texas 4,066 followers

Pioneering a Multi-Antigen Approach

About us

We are a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s unique cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize multiple tumor associated antigens (multiTAA) and kill tumor cells expressing those targets. Once infused into patients, this population of multiTAA-specific T cells attacks multiple tumor targets and acts to activate the patient’s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies.

Industry
Pharmaceutical Manufacturing
Company size
11-50 employees
Headquarters
Houston, Texas
Type
Public Company
Founded
2018
Specialties
Immunotherapy and T Cell Based Therapies

Locations

Employees at Marker Therapeutics, Inc.

Updates

Similar pages

Browse jobs

Funding